12:00 AM
 | 
Jun 18, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Syncria albiglutide: Additional Phase III data

Additional data from the open-label, international Phase III Harmony 6 trial in about 500 Type II diabetics showed that once-weekly subcutaneous albiglutide plus Lantus insulin glargine led to a non-significant reduction in HbA1c from baseline to week 52 (1.01% vs. 0.85%) and a non-significant increase in the proportion of patients achieving Hb1Ac <=7% at week 52 (45% vs. 30%) vs. preprandial insulin lispro plus Lantus. Albiglutide plus Lantus did significantly reduce body weight from baseline...

Read the full 363 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >